Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 4 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
6 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

Prostate cancer treatment heightens risk of dementia

30 Aug 2020

Prostate cancer patients receiving treatment with androgen deprivation therapy (ADT) are at increased risk of developing all-cause dementia or Alzheimer’s disease, a study has found.

Researchers looked at 100,414 men aged ≥66 years (median, 73 years; 84 percent white) who were diagnosed with locally advanced prostate cancer (cT1–cT4). None of them had a history of stroke, dementia, and use of psychiatric services.

In total, 37,911 men (38 percent) received ADT within 6 months of diagnosis, of whom 19,854 (53 percent) used ADT for >7 months. Compared with nonusers, ADT recipients were older (median age, 75 vs 72 years) at diagnosis, more likely to have received radiotherapy (64 percent vs 37 percent), have more comorbidities (≥2: 38 percent vs 31 percent), and have more advanced clinical tumour stage

Over 36 months of follow-up, 3,988 men were diagnosed with dementia, 1,797 developed Alzheimer’s, and 2,208 men utilized psychiatric services. These outcomes occurred more frequently among men exposed vs not exposed to ADT (dementia: 5.1 percent vs 3.3 percent; Alzheimer’s: 2.4 percent vs 1.4 percent; use of psychiatric services: 2.5 percent vs 2.0 percent).

Inverse-probability weighted Fine-Gray model showed that receipt of any pharmacologic ADT conferred a 17-percent higher risk of all-cause dementia (hazard ratio [HR], 1.17, 95 percent confidence interval [CI], 1.07–1.27), 23-percent higher risk of Alzheimer’s (HR, 1.23, 95 percent CI, 1.11–1.37), and 10-percent higher risk of psychiatric services use, although this was not significant (HR, 1.10, 95 percent CI, 1.00–1.22).

The risk was more pronounced among men with longer ADT exposure (≥7 months), which was associated with a 25-percent risk increase for all-cause dementia and 34 percent for Alzheimer’s.

The potential of a higher risk of dementia should be investigated further and weighed against the benefits of ADT in the present population, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 4 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
6 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.